DocWire News Editors

DocwireNews

New data presented at the annual meeting show that secukinumab (SEC) provided sustained 
improvements in the signs and symptoms of psoriatic arthritis (PsA) through five years of treatment. Efficacy improved with dose escalation, and the treatment was well tolerated, with a safety profile similar to earlier reports.SEC is a fully human monoclonal IgG1 antibody that selectively targets interleukin-17A. In previous reports from the FUTURE study, SEC was shown to provide rapid and significant improvements in all 
key clinical domains of (PsA) through three years.The original study included 606 adults with active PsA, and 460 entered the extension study. The amended protocol indicated that patients would receive dose escalation from 150 mg to 300 mg and from 75 mg to 150/300 mg from week 156 based on physician judgment.At week 260, assessments included American College of Rheumatology 20/50/70 Criteria, Psoriasis Area and Severity Index 90 score, Health Assessment Questionnaire Disability Index, and the 36-Item Short Form Health Survey Physical Component Summary, as well as whether dactylitis and enthesitis resolved.Philip J. Mease, MD, of the University of Washington in Seattle, and colleagues reported that more than 80% of patients who entered the extension study completed five years of treatment, and clinical responses were sustained or further improved through five years of treatment. Furthermore, 86 of 236 patients (36.4%) receiving SEC 150 mg were escalated to 300 mg, and 180 of 221 patients (81.4%) receiving SEC 75 mg were escalated to 150/300 mg. Dose escalation improved efficacy.

Jordana Jampel

Cutaneous Melanoma: Sun Protection Behaviors and UV Exposure in Canada

Melanoma

Leah Lawrence

Significant Cardiac Benefit Seen With Ifetroban in Patients With Duchenne Muscular Dystrophy

Neurology

Apitegromab Improved Motor Function in Type 2/3 Spinal Muscular Atrophy

Latest News

Secukinumab Provides Sustained Improvements in Psoriatic Arthritis

ACR 2018 Conference

New data presented at the annual meeting show that secukinumab (SEC) provided sustained ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe